Jose Manuel Brea Floriani
University of Santiago de Compostela, Spain
5th HTRF Symposium, Avignon, France
In the last years a revolution in the drug discovery paradigm has arisen by to the Open Innovation model, where the pharmaceutical companies open their doors to biotechnological companies and public research institutions. This model establishes networks of partners under an efficient leadership which allows increasing the R&D productivity (1,2). A succesful example of this open innovation model in Spain is the CENIT projects. They are mixed projects shared by the companies and the Spanish government, involving the participation of SMEs and public research groups, as well. The BioFarma research group/USEF screening platform participates in two CENIT projects with the biggest pharmaceutical companies in Spain, Laboratorios Almirall, Laboratorios Esteve and Draconis Pharma -former Laboratorios Palau Pharma: GENIUS PHARMA, which was devoted to develop public research platforms in Spain specialized in drug discovery for establishing partnerships with pharmaceutical companies, and currently NEOGENIUS PHARMA. The NEOGENIUS PHARMA is devoted to the discovery of first in class clinical candidates for pain. The project began by studying three targets whose in vitro activity was evaluated by using HTRF® technology. For this, three different assays were developed in close collaboration between the three companies and public research groups. These assays were used for carrying out HTS campaigns with the chemical libraries of the three companies obtaining several hits at each of the targets. These hits were then optimized in the public research platforms and used for carrying out the target validation. In our case, the USEF screening platform carried out all the in vitro assays of this phase. The primary assays were also carried out by using HTRF® technology. During these years we have screened more than 2400 compounds in more than 11000 assays, with a 90% of assays fulfilling the commonly accepted quality criteria, evidencing a high robustness and reliability of these assays. These assays allowed us to identify compounds acting at each of the targets which were useful to validate one of them as a new target for pain treatment. 1.- Paul SM et al., Nat Rev Drug Discov 2010; 9:203-214. 2.- Hunter J. Drug Discov World 2010; Fall:9-14"